Department of Clinical Physics & Bioengineering (DCPB)

NHS Greater Glasgow & Clyde, Scotland

NHS GGC logo

Research:

Tracer Development

The tracer development programme aims to develop novel radiopharmaceuticals for use in clinical molecular imaging. Molecular imaging can be used across the field of medicine to provide information about disease mechanisms, diagnosis of disease, identification of drug target and monitoring of therapeutic response. Our tracer development group has a focus on developing tracers for neuroimaging applications.

People:

Facilities:

The radiopharmacy located at the Western Infirmary contains a specialised facility and has staff with expertise for the production of novel radiopharmaceuticals under an MAIMP license in compliance with GMP regulations. This makes it one of the few centres in the UK that can produce novel radiotracers for clinical research studies.

For the development of novel tracers we have: -

123I-PK11195

Tracers Available

Target

123I-AMT

protein synthesis

123I-FIAU

viral thymidine kinase

123I-bCIT

dopamine / serotonin transporters

123I-5I-A85380

a4b2 nicotinic receptor

123I-mIBG (n.c.a)

noradrenaline transporter

123I-IQNB

M1/M4 muscarinic receptor

123I-CNS1261

activated NMDA receptor

123I-IUDR

cell proliferation

123I-IBVM

vesicular acetylcholine transporter

peripheral benzodiazepene receptor

123I-mZIENT

serotonin transporter

Tracers in Development Target

123I-compound

histamine H3 receptor

123I-compound

peripheral benzodiazepene receptor

123I-compound

noradrenaline transporter

123I-compound

mGluR 2/3 receptors

Clinical Studies:

Clinical imaging studies using novel neuroimaging SPECT radiotracers are conducted on a dedicated NeuroSPECT camera at the Southern General Hospital in Glasgow.


Funding:

neurosciences foundation

Chief Scientist's Office

Copyright DCPB (NHS GGC) © 2011.